# Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses

> **NCT01475071** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 100 (actual)

## Conditions studied

- Actinic Keratoses

## Interventions

- **DRUG:** Metvix and natural daylight PDT
- **DRUG:** Metvix and conventional PDT

## Key facts

- **NCT ID:** NCT01475071
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-11
- **Final completion:** 2013-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475071, "Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01475071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*